In the era of cancer immunotherapy, with the release of more clinical trial results, the use of ICIs is more and more widely, but about 40% of these patients will experience irAEs, even some patients with fatal irAEs, early identification of irAEs can reduce irAEs related deaths and medical costs, and biomarkers are an important indicator of early identification of toxic reaction caused by ICIs. We review the latest progress in predicting biomarkers of irAEs, guiding the study of more convenient and fast predictors or predictive models through the combing of biomarkers, ultimately serving clinical work.